

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤醫藥集團有限公司

China Resources Pharmaceutical Group Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3320)

ANNOUNCEMENT

UNAUDITED FINANCIAL RESULTS OF CR DOUBLE-CRANE FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2025

On 24 October 2025, CR Double-Crane released its quarterly report for the nine months ended 30 September 2025.

China Resources Double-Crane Pharmaceutical Co., Ltd. (華潤雙鶴藥業股份有限公司) (“**CR Double-Crane**”) is a company incorporated in the People’s Republic of China. The shares of CR Double-Crane are listed on the Shanghai Stock Exchange. As of the date of this announcement, CR Double-Crane is indirectly owned as to 60.24% by China Resources Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) and is a subsidiary of the Company.

On 24 October 2025, CR Double-Crane released its quarterly report for the nine months ended 30 September 2025 (the “**CR Double-Crane Unaudited Financials**”). Set out below is the key financial information of the CR Double-Crane Unaudited Financials:

	For the nine months ended	
	30 September	
	2025	2024
	(RMB)	(RMB)
	(unaudited)	(unaudited)
Revenue	8,283,222,411.30	8,548,241,751.78
Net profit	1,388,212,831.84	1,411,764,462.20
Net decrease in cash and cash equivalents	(630,388,437.05)	(509,288,867.81)
Cash and cash equivalents at the end of the period	2,207,726,715.86	2,698,854,450.15
	As of	As of
	30 September	31 December
	2025	2024
	(RMB)	(RMB)
	(unaudited)	(audited)
Total assets	17,013,714,914.48	16,685,995,679.77
Total liabilities	4,852,945,043.03	5,574,240,762.32
Owner’s equity	12,160,769,871.45	11,111,754,917.45

The CR Double-Crane Unaudited Financials have been prepared in accordance with the PRC Generally Accepted Accounting Principles, have not been reviewed or audited by the Company’s auditors, and may require adjustments during the course of auditing. The financial information is limited to CR Double-Crane only and does not represent or provide a complete view of the operational or financial status of the Group. **Shareholders and potential investors should exercise caution when dealing in securities of the Company and should not rely solely on such information.**

For further details of the CR Double-Crane Unaudited Financials, please refer to the quarterly report for the nine months ended 30 September 2025 published by CR Double-Crane on the website of the Shanghai Stock Exchange (www.sse.com.cn).

By order of the Board
China Resources Pharmaceutical Group Limited
Mr. Bai Xiaosong
Chairman

PRC, 24 October 2025

As at the date of this announcement, the Board comprises Mr. Bai Xiaosong as chairman and executive director; Mr. Cheng Jie and Mr. Liu Changan as executive directors; Mdm. Guo Wei, Mr. Sun Yongqiang, Mr. Wang Yuhang, Mr. Guo Chuan and Mdm. Jiao Ruifang as non-executive directors and Mdm. Chiu Mun Wai, Mr. Fu Tingmei, Mr. Zhang Kejian and Mr. Shi Luwen as independent non-executive directors.